Peptide Comparison
Ipamorelin vs Tesamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin has stronger documented evidence (FDA-Approved) than Ipamorelin (Anecdotal + Phase 2) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Used together in
- Fat Loss GH: Visceral fat reduction + GH pulse
Shared safety considerations
Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Ipamorelin | Tesamorelin | |
|---|---|---|
| Class | Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist | GHRH analog (FDA-approved) |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise | Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion |
| Route | SC injection | SC injection |
| Half-life | ~2 hrs | ~26 min |
| Dosage (research) | 200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC) | 2 mg SC daily (FDA label) |
| Evidence tier | Anecdotal + Phase 2 | FDA-Approved |
| Research depth | 64 indexed | 127 indexed |
| Availability | Compounding Restricted | Prescription |
| Reported risks | Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical | Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Ipamorelin or Tesamorelin?
Tesamorelin has stronger documented evidence (FDA-Approved) than Ipamorelin (Anecdotal + Phase 2) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Ipamorelin and Tesamorelin?
Ipamorelin is classed as Growth hormone-releasing peptide (GHRP); ghrelin receptor agonist; Tesamorelin is classed as GHRH analog (FDA-approved). Reported mechanism: Ipamorelin, Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise; Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion. Reported half-life: Ipamorelin, ~2 hrs; Tesamorelin, ~26 min. Routes in published studies: Ipamorelin, SC injection; Tesamorelin, SC injection.
Which has stronger evidence, Ipamorelin or Tesamorelin?
Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Ipamorelin is graded Anecdotal + Phase 2, with 9 cited sources on its reference page and 64 indexed studies. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies.
Which is more accessible, Ipamorelin or Tesamorelin?
Tesamorelin is FDA-approved and Ipamorelin is not. Catalog status: Ipamorelin, Compounding Restricted; Tesamorelin, Prescription. FDA lists Ipamorelin in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are Ipamorelin and Tesamorelin ever combined?
Yes. Fat Loss GH is a documented stack containing both Ipamorelin and Tesamorelin; the stack page gives the stated rationale.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…